Display options
Cite
Jing W, Gershan JA, Weber J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3(1):2doi: 10.1186/s40425-014-0043-z.
Jing, W., Gershan, J. A., Weber, J., Tlomak, D., McOlash, L., Sabatos-Peyton, C., & Johnson, B. D. (2015). Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. Journal for immunotherapy of cancer, 3(1), 2. https://doi.org/10.1186/s40425-014-0043-z
Jing, Weiqing, et al. "Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma." Journal for immunotherapy of cancer vol. 3,1 (2015): 2. doi: https://doi.org/10.1186/s40425-014-0043-z
Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015 Jan 20;3(1):2. doi: 10.1186/s40425-014-0043-z. eCollection 2015. PMID: 25614821; PMCID: PMC4302511.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2015 Jan 20;3(1):2. doi: 10.1186/s40425-014-0043-z. eCollection 2015.

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.

Journal for immunotherapy of cancer

Weiqing Jing, Jill A Gershan, James Weber, Dominique Tlomak, Laura McOlash, Catherine Sabatos-Peyton, Bryon D Johnson

Affiliations

  1. Division of Hematology/Oncology/Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226 USA.
  2. Novartis Institutes for BioMedical Research, Inc., Cambridge, MA 02139 USA.

PMID: 25614821 PMCID: PMC4302511 DOI: 10.1186/s40425-014-0043-z

Abstract

BACKGROUND: Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require multi-faceted approaches incorporating conventional drug therapies, immunotherapy and other novel treatments. Our lab previously showed that a combination of transient lymphodepletion (sublethal whole body irradiation) and PD-1/PD-L1 blockade generated anti-myeloma T cell reactivity capable of eliminating established disease. We hypothesized that blocking a combination of checkpoint receptors in the context of low-dose, lymphodepleting whole body radiation would boost anti-tumor immunity.

METHODS: To test our central hypothesis, we utilized a 5T33 murine multiple myeloma model. Myeloma-bearing mice were treated with a low dose of whole body irradiation and combinations of blocking antibodies to PD-L1, LAG-3, TIM-3, CD48 (the ligand for 2B4) and CTLA4.

RESULTS: Temporal phenotypic analysis of bone marrow from myeloma-bearing mice demonstrated that elevated percentages of PD-1, 2B4, LAG-3 and TIM-3 proteins were expressed on T cells. When PD-L1 blockade was combined with blocking antibodies to LAG-3, TIM-3 or CTLA4, synergistic or additive increases in survival were observed (survival rates improved from ~30% to >80%). The increased survival rates correlated with increased frequencies of tumor-reactive CD8 and CD4 T cells. When stimulated in vitro with myeloma cells, CD8 T cells from treated mice produced elevated levels proinflammatory cytokines. Cytokines were spontaneously released from CD4 T cells isolated from mice treated with PD-L1 plus CTLA4 blocking antibodies.

CONCLUSIONS: These data indicate that blocking PD-1/PD-L1 interactions in conjunction with other immune checkpoint proteins provides synergistic anti-tumor efficacy following lymphodepletive doses of whole body irradiation. This strategy is a promising combination strategy for myeloma and other hematologic malignancies.

Keywords: 2B4; Blockade; CTLA4; Immune checkpoint proteins; LAG-3; Low dose whole body irradiation; Myeloma; PD-L1; TIM-3

References

  1. Trends Immunol. 2012 Jul;33(7):364-72 - PubMed
  2. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  3. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80 - PubMed
  4. Trends Mol Med. 2008 Dec;14(12):550-9 - PubMed
  5. Exp Hematol. 2010 Feb;38(2):124-31 - PubMed
  6. Eur J Immunol. 2012 Mar;42(3):651-61 - PubMed
  7. Cancer Immunol Res. 2014 May;2(5):410-22 - PubMed
  8. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80 - PubMed
  9. Clin Cancer Res. 2010 Dec 15;16(24):6019-28 - PubMed
  10. Biochim Biophys Acta. 2013 Aug;1836(1):177-85 - PubMed
  11. J Immunol. 2011 Apr 1;186(7):4200-12 - PubMed
  12. J Clin Oncol. 2010 Jul 1;28(19):3167-75 - PubMed
  13. Cancer Res. 2014 Feb 15;74(4):1045-55 - PubMed
  14. Cancer Res. 2013 Jan 15;73(2):605-16 - PubMed
  15. Science. 1995 Nov 10;270(5238):985-8 - PubMed
  16. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  17. Clin Cancer Res. 2009 Feb 1;15(3):971-9 - PubMed
  18. Biol Blood Marrow Transplant. 2011 Aug;17 (8):1133-45 - PubMed
  19. J Immunother. 2010 Apr;33(3):225-35 - PubMed
  20. Cancer Res. 2014 Jul 1;74(13):3418-28 - PubMed
  21. Clin Cancer Res. 2013 Jan 15;19(2):462-8 - PubMed
  22. Nat Immunol. 2011 Jun;12(6):492-9 - PubMed
  23. J Immunol. 1998 Apr 15;160(8):3855-60 - PubMed
  24. Cancer Immunol Res. 2014 Feb;2(2):142-53 - PubMed
  25. Clin Cancer Res. 2013 Oct 15;19(20):5626-35 - PubMed
  26. Nat Rev Immunol. 2008 Jun;8(6):467-77 - PubMed
  27. Front Immunol. 2013 Dec 19;4:455 - PubMed
  28. PLoS One. 2014 May 05;9(5):e93523 - PubMed
  29. Immunity. 2014 Feb 20;40(2):289-302 - PubMed
  30. Cancer Res. 2011 May 15;71(10 ):3540-51 - PubMed
  31. Cell Immunol. 2012 Jul-Aug;278(1-2):76-83 - PubMed
  32. Blood. 2010 Sep 30;116(13):2286-94 - PubMed
  33. J Exp Med. 2000 Jul 17;192(2):303-10 - PubMed
  34. Clin Cancer Res. 2007 Apr 1;13(7):2151-7 - PubMed
  35. J Exp Med. 2010 Sep 27;207 (10 ):2187-94 - PubMed
  36. Cancer Immunol Res. 2014 May;2(5):393-8 - PubMed
  37. J Immunol. 2012 Apr 1;188(7):2957-65 - PubMed
  38. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  39. J Immunother. 2011 Jun;34(5):409-18 - PubMed
  40. J Clin Invest. 2012 Apr;122(4):1271-82 - PubMed
  41. J Exp Med. 2009 Aug 3;206(8):1717-25 - PubMed
  42. J Clin Invest. 2011 Jun;121(6):2350-60 - PubMed
  43. PLoS Pathog. 2011 May;7(5):e1002045 - PubMed
  44. Annu Rev Immunol. 2005;23:515-48 - PubMed
  45. Science. 2007 Nov 16;318(5853):1141-3 - PubMed
  46. Immunity. 2007 Oct;27(4):670-84 - PubMed
  47. Cancer Res. 2012 Oct 15;72(20):5209-18 - PubMed
  48. J Clin Invest. 2014 May;124(5):2246-59 - PubMed
  49. J Immunol. 2011 Oct 1;187(7):3493-8 - PubMed
  50. Oncoimmunology. 2012 Nov 1;1(8):1239-1247 - PubMed
  51. Semin Oncol. 2010 Oct;37(5):499-507 - PubMed
  52. Cancer Res. 2014 Jan 15;74(2):633-4; discussion 635 - PubMed
  53. Cancer Res. 2012 Feb 15;72(4):917-27 - PubMed
  54. J Exp Med. 2010 Sep 27;207 (10 ):2175-86 - PubMed
  55. J Immunol. 2013 May 1;190(9):4899-909 - PubMed
  56. Immunology. 2010 Apr;129(4):474-81 - PubMed
  57. Cancer Immunol Immunother. 2013 Apr;62(4):629-37 - PubMed
  58. Int Immunol. 2005 Feb;17(2):133-44 - PubMed
  59. J Immunol. 2001 Dec 15;167(12 ):6706-10 - PubMed
  60. Blood. 2007 Jul 1;110(1):296-304 - PubMed
  61. J Immunol. 2006 Mar 1;176(5):2758-64 - PubMed
  62. Blood. 2011 Apr 28;117(17 ):4501-10 - PubMed
  63. J Exp Med. 2013 Aug 26;210(9):1695-710 - PubMed
  64. Br J Haematol. 2012 Jan;156(2):213-24 - PubMed
  65. J Immunol. 2013 Jun 1;190(11):5620-8 - PubMed

Publication Types